Critical role of AT1 receptor expression after lschemia/reperfusion in isolated rat hearts: Beneficial effect of antisense oligodeoxynucleotides directed AT1 receptor mRNA

Circulation Research

Volumn 83, Issue 5, 1998, Pages 552-559

  Yang, B C ^a   Phillips, M I ^a   Zhang, Y C ^a   Kimura, B ^a   Shen, L P ^a   Mehta, P ^a   Mehta, J L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin II; Antisense; AT1 receptor; Ischemia reperfusion; Losartan; mRNA

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTISENSE OLIGODEOXYNUCLEOTIDE; LOSARTAN; MESSENGER RNA; RECEPTOR SUBTYPE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; ISCHEMIC HEART DISEASE; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANALYSIS OF VARIANCE; ANIMAL; BIOSYNTHESIS; BLOOD; DRUG ANTAGONISM; GENETICS; IN VITRO STUDY; METABOLISM; REPERFUSION INJURY; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANIMALS; LOSARTAN; MALE; MYOCARDIAL REPERFUSION INJURY; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RNA, MESSENGER;

EID: 0032493936     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.83.5.552     Document Type: Article

References (53)

1. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
2. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, Taft CS, Perryman MB. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet. 1993;342:1073-1075.
3. Marian AJ, Yu QT, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1993;342:1085-1086.
4. Ohishi M, Fujii K, Minamino T, Higaki J, Kamitani A, Rakugi H, Zhao Y, Mikami H, Miki T, Ogihara T. A potent genetic risk factor for restenosis. Nat Genet. 1993;5:324-325.
5. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324: 1098-1104.
6. Fleetwood G, Boutinet S, Meier M, Wood JM. Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart. J Cardiovasc Pharmacol. 1991; 17:351-356.
7. Dzau VJ. Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens. 1994;12(suppl):S3-S10.
8. Vaughan DE, Declerck PJ, Vanhoutte P, De Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemost. 1992;68:60-63.
9. Rydzewski B, Zelezna B, Tang W, Sumners C, Raizada MK. Angiotensin II stimulation of plasminogen activator inhibitor-1 gene expression in astroglial cells from the brain. Endocrinology. 1992;130:1255-1262.
10. 31P nuclear magnetic resonance. J Cardiovasc Pharmacol. 1994;24:573-586.
11. Yoshiyama M, Kim S, Yamagishi H, Omura T, Tant T, Yanagi S, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T. Cardioprotective effect of the angiotensin II type 1R antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J. 1994;128:1-6.
12. Pfeffer M, Braunwald E, Boye L, the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327: 669-677.
13. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
14. Sechi LA, Griffin CA, Grady EF, Kalinyak JE, Schambelan M. Characterization of angiotensin II receptor subtypes in rat heart. Circ Res. 1992;71:1482-1489.
15. Allen AM, Yamada H, Mendelsohn FA. In vitro autoradiographic localization of binding to angiotensin receptors in the heart. Int J Cardiol. 1990;28:25-33.
16. Sun Y, Weber KT. Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. J Lab Clin Invest. 1993;122:404-411.
17. Feolde E, Vigne P, Frelin C. Angiotensin II receptor subtypes and biological response in the rat heart. J Mol Cell Cardiol. 1993;25:1359-1367.
18. Sun Y, Weber KT. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res. 1994;28:1623-1628.
19. Yang BC, Phillips MI, Ambuhl PEJ, Shen LP, Mehta P, Mehta JL. Increase in angiotensin II type 1 receptor expression immediately following ischemia-reperfusion in isolated rat hearts. Circulation. 1997;96: 922-926.
20. 1R mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul Pept. 1993;49: 167-174.
21. Phillips MI, Wielbo D, Gyurko R. Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes. Kidney Int. 1994; 46:1554-1556.
22. Ambuhl PEJ, Gyurko R, Phillips MI. A decrease of angiotensin receptor number in rat brain nuclei by antisense oligonucleotides against the angiotensin AT1A receptor. Regul Pept. 1995;59:171-182.
23. Wielbo D, Sernia C, Gyurko R, Phillips MI. Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension. 1995; 25:314-319.
24. Wielbo D, Simon A, Phillips MI, Toffolo S. Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension. 1996;28:147-151.
25. Felgner PL. Cationic liposome-mediated transfection with lipofection reagent. Methods Mol Biol. 1991:91-98.
26. Neely TR, Rovetto MJ. Techniques for perfusing isolated rat hearts. Methods Enzymol. 1975;39:43-60.
27. Scholkens BA, Linz W, Lindpainter K, Ganten D. Angiotensin deteriorates but bradykinin improves cardiac function following ischemia in isolated rat hearts. J Hypertens. 1987;5(suppl 5):S7-S9.
28. Chen LY, Mehta P, Mehta JL. Oxidized-LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance in the effect of oxidized-LDL on platelet function. Circulation. 1996;93:1740-1746.
29. Chomczynski PK, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
30. 1 angiotensin II receptor that is present in proximal tubule epithelium. Am J Physiol. 1993;264:F645-F654.
31. Lu D, Yang H, Shaw G, Raizada M. Angiotensin II-induced nuclear targeting of the AT1 receptor in brain neurons. Endocrinology. 1998; 139:1-11.
32. Samani NJ, Morgan K, Brammar WJ, Swales JD. Detection of renin messenger RNA in rat tissues: increased sensitivity using an RNAse protection technique. J Hypertens. 1987;5(suppl 2):S19-S21.
33. Campbell DJ, Habener JF. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest. 1986;78: 31-39.
34. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research? J Hypertens. 1994;12(suppl 2): S1-S5.
35. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749-756.
36. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic factor inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest. 1990;86:1690-1697.
37. Naftilan AJ, Pratt RE, Dzau VJ. Induction of PDGF A-chain and c-myc gene expression by angiotensin II in cultured vascular smooth muscle cells. J Clin Invest. 1989;83:1419-1424.
38. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell response to angiotensin II. J Clin Invest. 1993;91:2268-2274.
39. Reiss K, Capasso JM, Huang HE, Megg LG, Li P, Anversa P. Ang II receptors, c-myc and c-jun, in myocytes after myocardial infarction and ventricular failure. Am J Physiol. 1993;264:H760-H769.
40. Meggs LG, Coupet J, Huang H, Cheng W, Li P, Capasso JM, Homey CJ, Anversa P. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res. 1993;72:1149-1162.
41. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infraction. J Clin Invest. 1995;95:46-54.
42. Harada K, Komuro I, Hayshi D, Sugaya T, Murakami K, Yazaki Y. Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias. Circulation. 1998;97:315-317.
43. Phillips MI, Mohuczy-Dominiak D, Cofey M, Galli SM, Kimura P, Wu P, Zelles T. Prolonged reduction of high blood pressure with an in vivo, non-pathogenic, adeno-associated viral vector delivery of AT1-mRNA antisense. Hypertension. 1997;29:374-380.
44. Phillips MI. Antisense inhibition al vector delivery for reducing hypertension. Hypertension. 1997;29:177-187.
45. Lu D, Yu K, Raizada MK. Retrovirus-mediated transfer of an angiotensin II type 1R (AT1-R) antisense sequence decreases AT 1-receptors and angiotensin II action in astroglial and neuronal cells in primary cultures from the brain. Proc Natl Acad Sci U S A. 1995;92:1162-1166.
46. Iyer S, Lu D, Katovich MJ, Raizada MK. Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type-1R antisense. Proc Natl Acad Sci U S A. 1996;93:9960-9965.
47. Ribuot C, Yamaguchi N, Godin D, Jette L, Nadeau R. Intracoronary administration of saralasin: effects on cardiac arrhythmias induced by ischemia and reperfusion in the anaesthetised dog. Cardiovasc Res. 1992; 26:968-972.
48. Yang BC, Virmani R, Nichols WW, Mehta JL. Platelets protect against myocardial dysfunction and injury induced by ischemia and reperfusion in isolated rat hearts. Circ Res. 1993;72:1181-1190.
49. Yang BC, Chen LY, Saldeen TGP, Mehta JL. Reperfusion injury in the endotoxin-treated rat heart: reevaluation of the role of nitric oxide. Br J Pharmacol. 1997;120:305-311.
50. Ford WR, Chanachan AS, Jugdutt BI. Opposite effects of angiotensin AT1 and AT2 receptor, antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation. 1996;94:3087-3089.
51. Yamada T; Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A. 1996;93:156-160.
52. Cigola EC, Kajstura J, Li B, Meggs LG, Anversa P. Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res. 1997; 231:363-371.
53. 1 receptor antagonist losartan [abstract]. Circulation. 1997;96(suppl I):I-418.